Beating the Blues - a randomized controlled clinical trial on computerized cognitive behavior therapy for mild to moderate depression in the Netherlands.

Published: 19-08-2011 Last updated: 19-03-2025

The primary objective of this trial is to determine the clinical and cost effectiveness of computerized cognitive behavioural therapy with therapist support, compared to face-to face therapy based on cognitive-behavioural techniques for mild to...

Ethical review Approved WMO **Status** Will not start

Health condition type Mood disorders and disturbances NEC

Study type Interventional

Summary

ID

NL-OMON36592

Source

ToetsingOnline

Brief title

Beating the Blues

Condition

Mood disorders and disturbances NEC

Synonym

depressive symptoms; melancholy

Research involving

Human

Sponsors and support

Primary sponsor: Interhealth

1 - Beating the Blues - a randomized controlled clinical trial on computerized cogni ... 7-05-2025

Source(s) of monetary or material Support: Interhealth B.V.

Intervention

Keyword: Beating the Blues, Cognitive behavior therapy, Internet therapy, RCT

Outcome measures

Primary outcome

The main study parameter is the presence/ severity of depressive symptoms as measured with the Beck Depression Inventory. Measurement takes place over time at (1) baseline, (2) post-treatment, (3) six-month follow-up and (4) twelve-month follow-up.

Other clinical and economic questionnaires will be used to back up the main study parameter (see Table 7 1 in protocol) . More specifically, they will be used to answer the research questions about (cost) effectiveness.

Secondary outcome

The secondary study parameters are: (1) client acceptability ratings, as measured with the (composed) questionnaire AFQ; (2) presence/ severity of anxiety symptoms, as measured with the anxiety subscale of the CORE-34 and with the GAD-7.

Age, sex, social economic status and ethnical background will be used as prognostic factors (3).

Study description

Background summary

Our general aim is to evaluate the Dutch version of Beating the Blues, a computer-based cognitive behavioural therapy for mild to moderate depressive complaints, offered in conjunction with limited therapist support. The effectiveness of Beating the Blues has been established in the UK, but not yet in the Netherlands. However, the program is currently used in Dutch practices of Mentaal Beter, as an alternative to face-to-face therapy based on cognitive-behavioural techniques. On the basis of the available literature, we hypothesize that computerized cognitive-behavioural therapy with limited therapist support is not inferior to face-to-face therapy based on cognitive-behavioural techniques.

Study objective

The primary objective of this trial is to determine the clinical and cost effectiveness of computerized cognitive behavioural therapy with therapist support, compared to face-to face therapy based on cognitive-behavioural techniques for mild to moderate depressive symptoms. Secondary objectives include the acceptability of the two forms of treatment, as well as their influence on symptoms of anxiety. Additionally, predictors and moderators of outcome will be investigated.

Study design

A non-inferiority randomized clinical trial will be conducted, with 374 participants randomly allocated to either computerized cognitive-behavioural therapy with limited therapist support or face-to-face therapy based on cognitive-behavioural techniques. We will make use of blocked randomization to assure an equal amount of participants in each group. Blinding is not possible - both the researcher and the participant are aware of the allocated condition, but only so after the screening and randomization. The study will be preceded by an external pilot, with 30 participants.

Intervention

Beating the Blues consists of eight fifty-minute (inter)active modules with a cognitive-behavioural content, elucidated by several returning case studies. Each session ends with a summary and with home-work assignments. The Dutch version of Beating the Blues is offered with limited therapist support (three face-to-face contacts).

Study burden and risks

It is unlikely that Beating the Blues or the treatment as usual will lead to serious adverse events. As such, the study poses no risk to the participants. However, the participants are asked to invest time into this study. The screening will be conducted by telephone and will take approximately 30-40 minutes. Furthermore, over a one-year period, four sets of questionnaires will be offered via the internet. It will approximately take 30-50 minutes to complete each set of questionnaires.

Contacts

Public

Interhealth

Asterweg 19D12; unit 12 1031 HL, Amsterdam NL Scientific

Interhealth

Asterweg 19D12; unit 12 1031 HL, Amsterdam NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

BDI-II-NL range 14 to 28; Duration complaints >= two months; Age range 18 to 65; Native Dutch speaker; Access to internet and e-mail at home

4 - Beating the Blues - a randomized controlled clinical trial on computerized cogni ... 7-05-2025

Exclusion criteria

Other psychological treatment for complaints; Presence of suicide ideation (currently); Severe co-morbid disorders; Substance abuse (alcohol/ drugs)

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Will not start Start date (anticipated): 15-06-2011

Enrollment: 404

Type: Anticipated

Ethics review

Approved WMO

Date: 19-08-2011

Application type: First submission

Review commission: METIGG: Medisch Ethische Toetsingscommissie Instellingen

Geestelijke Gezondheidszorg (Utrecht)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID

ID: 22545 Source: NTR

Register

Title:

In other registers

Register	10
CCMO	NL33917.097.10
OMON	NL-OMON22545